Brexpiprazole for the maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy

References

• CitromeLStensbølTBMaedaKThe preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?Expert Rev Neurother201515101219122926402059
   PubMed Web of Science ®Google Scholar
• CitromeLThe ABC’s of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents outInt J Clin Pract201569111211122026477545
   PubMed Web of Science ®Google Scholar
• OtsukaREXULTI (brexpiprazole) tablets, for oral use2018 Available from: https://www.otsuka-us.com/media/static/Rexulti-PI.pdfAccessed December 26, 2018
   Google Scholar
• KaneJMSkubanAOuyangJA multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophreniaSchizophr Res20151641–312713525682550
   PubMed Web of Science ®Google Scholar
• CorrellCUSkubanAOuyangJEfficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled TrialAm J Psychiatry2015172987088025882325
   PubMed Web of Science ®Google Scholar
• ThaseMEYouakimJMSkubanAEfficacy and safety of adjunctive brexpiprazole 2 Mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressantsJ Clin Psychiatry20157691224123126301701
   PubMed Web of Science ®Google Scholar
• ThaseMEYouakimJMSkubanAAdjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind studyJ Clin Psychiatry20157691232124026301771
   PubMed Web of Science ®Google Scholar
• FleischhackerWWHobartMOuyangJEfficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled studyInt J Neuropsychopharmacol2017201112127566723
   PubMed Web of Science ®Google Scholar
• IshigookaJIwashitaSTadoriYLong-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: a 52-week, open-label studyPsychiatry Clin Neurosci201872644545329582518
   PubMed Web of Science ®Google Scholar
• ForbesAHobartMOuyangJShiLPfisterSHakalaMA Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with SchizophreniaInt J Neuropsychopharmacol201821543344129415258
   PubMed Web of Science ®Google Scholar
• MaedaKSuginoHAkazawaHBrexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulatorJ Pharmacol Exp Ther2014350358960424947465
   PubMed Web of Science ®Google Scholar
• FrankelJSSchwartzTLBrexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazoleTher Adv Psychopharmacol201771294128101322
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. DSM-IV-TRWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• CitromeLBrexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract201569997899726250067
   PubMed Web of Science ®Google Scholar
• IshigookaJIwashitaSTadoriYEfficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: a 6-week, randomized, double-blind, placebo-controlled studyPsychiatry Clin Neurosci201872969270029774628
   PubMed Web of Science ®Google Scholar
• IvkovicJLindstenAGeorgeVErikssonHHobartMEffect of brexpiprazole on prolactin: an analysis of short- and long-term trials in schizophreniaEur Neuropsychopharmacol201727S957S958
   Web of Science ®Google Scholar
• ErikssonHWeissCHobartMOuyangJWeillerEEffect of brexpiprazole on weight and metabolic parameters: an analysis of short-and long-term trials in schizophreniaCNS Spectr201722164
   Google Scholar
• CitromeLOtaANagamizuKPerryPWeillerEBakerRAThe effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophreniaInt Clin Psychopharmacol201631419220126963842
   PubMed Web of Science ®Google Scholar
• CitromeLActivating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harmJ Clin Psychopharmacol201737213814728141623
   PubMed Web of Science ®Google Scholar
• BakMFransenAJanssenJvan OsJDrukkerMAlmost all anti-psychotics result in weight gain: a meta-analysisPLoS One201494e9411224763306
   PubMed Web of Science ®Google Scholar
• NewcomerJWErikssonHZhangPWeillerEWeissCChanges in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studiesCurr Med Res Opin201834122197220529985680
   PubMed Web of Science ®Google Scholar
• WeissCWeillerEBakerRAThe effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studiesInt Clin Psychopharmacol201833525526029878915
   PubMed Web of Science ®Google Scholar
• Ng-MakDTongbramVNdiranguKRajagopalanKLoebelAEfficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysisJournal of Comparative Effectiveness Research Epub4262018
   Web of Science ®Google Scholar
• CorrellCUCucchiaroJSilvaRHsuJPikalovALoebelALong-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension studyCNS Spectr201621539340227048911
   PubMed Web of Science ®Google Scholar
• AigbogunMSLiuSKamatSASapinCDuhigAMCitromeLRelapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USAClinicoecon Outcomes Res20181044345630147350
   PubMed Web of Science ®Google Scholar
• DurgamSEarleyWLiRLong-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trialSchizophr Res20161762–326427127427558
   PubMed Web of Science ®Google Scholar
• TandonRCucchiaroJPhillipsDA double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophreniaJ Psychopharmacol2016301697726645209
   PubMed Web of Science ®Google Scholar
• CorrellCUShiLWeissCSuccessful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment studyCNS Spectrums Epub10112018
   Web of Science ®Google Scholar
• LepolaUHeftingNZhangDHobartMAdjunctive brexpiprazole for elderly patients with major depressive disorder: an open-label, long-term safety and tolerability studyInt J Geriatr Psychiatry201833101403141030039634
   PubMed Web of Science ®Google Scholar